Document is current
Any future updates will be listed below
-
Authors
Ling, Xiang
Wu, Wenjie
Fan, Chuandong
Xu, Chao
Liao, Jianqun
Rich, Laurie J.
Huang, Ruea-Yea
Repasky, Elizabeth A.
Wang, Xinjiang
Li, Fengzhi
-
Funding
Funding for this research was provided by:
National Institutes of Health (R21CA180764, R03CA182552, R44CA176937)
- License Information
-
More Information
Article History
Received: 8 August 2018
Accepted: 31 August 2018
First Online: 3 October 2018
Ethics approval and consent to participate
: Human subject is not applicable in this study. All in vivo experimental studies were performed following the IACUC-approved mouse protocol, which was approved by the Institutional Animal Care and Use Committee (IACUC) at Roswell Park Comprehensive Cancer Center.
: Not applicable.
: FL118 and FL118 core structure-based analogues will be further developed in Canget BioTekpharma LLC (), a Roswell Park Comprehensive Cancer Center-spinoff company. XL, XW and FL are initial investors of Canget for development of FL118 and FL118 core structure-relevant anticancer agents.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
